Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials

Many countries have now started to roll out vaccination efforts to contain the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes the coronavirus disease 2019 (COVID-19).

One of the candidate vaccines, the adenovirus serotype 26 (Ad26) vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) or JNJ-78436735, is now in Phase 3 of human trials.

Developed by Janssen Vaccines (Johnson & Johnson) and Beth Israel Deaconess Medical Center (BIDMC), the vaccine is a single-dose human adenovirus vector vaccine, which has shown a 66-percent efficacy against SARS-CoV-2.

Study: Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques. Image Credit:  Andreas Prott / Shutterstock

A new study, conducted by researchers at the Harvard Medical School, Tufts University and the Massachusetts Institute of Technology in the U.S. and the Janssen Vaccines & Prevention BV in the Netherlands, showed that a single immunization with a low dose of the Ad26.COV2.S vaccine – also known as the ‘Johnson & Johnson vaccine’ – effectively protected against SARS-CoV-2 challenge in rhesus macaques.

The team also revealed that a higher vaccine dose might be needed to protect the upper respiratory tract compared with the lower respiratory tract.

The team’s findings have been released on the preprint bioRxiv* server.

The vaccine

The Ad26.COV2.S vaccine was derived from the first clinical isolate of the Wuhan strain. The Ad26 vector is used in the Ebola vaccine that was approved by the European Medicines Agency.

Ad26-based vaccines are safe and immunogenic since they are based on Janssen’s AdVac technology platform, which was also used to develop and manufacture other vaccine candidates against the Ebola virus, the human immunodeficiency virus (HIV), the respiratory syncytial virus (RSV), and the Zika virus.

The study

In previous SARS-CoV-2 vaccine studies in nonhuman primates, the protection in the upper respiratory tract tends to be less strong than the protection in the lower respiratory tract. This means that protecting against asymptomatic infection may become more difficult to achieve than protection against severe pneumonia in humans.

However, the role of vaccine doses in the protection of the upper and lower respiratory tracts remains unclear.

In the study, the researchers assessed the immunogenicity and protective efficacy of a titration of the Ad26.COV2.S dose levels to determine if it would still be effective against SARS-CoV-2.

The researchers vaccinated 30 rhesus macaques once with various doses of the vaccine, including 1x1011, 5x1010, 1.125x1010, or 2x109 vp Ad26.COV2.S or sham and were exposed to the virus by the intranasal and intratracheal routes.

Interestingly, the research findings showed that vaccination with doses as low as 2x109 bp provided strong and potent protection in bronchoalveolar lavage. Meanwhile, doses of 1.125x1010 vp were required for protection in nasal swabs.

The team noted that low doses of the vaccine protected against SARS-CoV-2 in the lower respiratory tract. However, they also found that higher doses are needed to protect the upper respiratory tract. Also, suboptimal vaccine dose levels have led to decreased efficacy to protect against the infection, while no evidence of vaccine-associated enhanced respiratory disease (VAERD) was noted.

The researchers observed that low doses of Ad26.COV2.S protected against the virus’s challenge in the lower respiratory tract, but that higher vaccine dose levels were required to protect in the upper respiratory tract. Suboptimal vaccine dose levels resulted in reduced protective efficacy, but no evidence of VAERD was observed.

There are currently 2 phase 3 human trials in progress to determine the safety and efficacy of the vaccine against the virus in a large group of people.

If the results are promising, the vaccine may be used alongside the current candidates to prevent infection in many countries.

*Important Notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Source:
Journal reference:
Angela Betsaida B. Laguipo

Written by

Angela Betsaida B. Laguipo

Angela is a nurse by profession and a writer by heart. She graduated with honors (Cum Laude) for her Bachelor of Nursing degree at the University of Baguio, Philippines. She is currently completing her Master's Degree where she specialized in Maternal and Child Nursing and worked as a clinical instructor and educator in the School of Nursing at the University of Baguio.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Laguipo, Angela. (2021, February 02). Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials. News-Medical. Retrieved on March 02, 2021 from https://www.news-medical.net/news/20210202/Johnson-Johnson-SARS-CoV-2-vaccine-shows-promise-in-clinical-trials.aspx.

  • MLA

    Laguipo, Angela. "Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials". News-Medical. 02 March 2021. <https://www.news-medical.net/news/20210202/Johnson-Johnson-SARS-CoV-2-vaccine-shows-promise-in-clinical-trials.aspx>.

  • Chicago

    Laguipo, Angela. "Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials". News-Medical. https://www.news-medical.net/news/20210202/Johnson-Johnson-SARS-CoV-2-vaccine-shows-promise-in-clinical-trials.aspx. (accessed March 02, 2021).

  • Harvard

    Laguipo, Angela. 2021. Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials. News-Medical, viewed 02 March 2021, https://www.news-medical.net/news/20210202/Johnson-Johnson-SARS-CoV-2-vaccine-shows-promise-in-clinical-trials.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Ivermectin may not be the ‘silver bullet’ antiviral against COVID-19